Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
959.41
+43.35 (4.73%)
At close: Nov 11, 2026, 4:00 PM EST
964.90
+5.49 (0.57%)
After-hours: Nov 11, 2026, 7:57 PM EST
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $5.12B in the quarter ending September 30, 2026, with 36.27% growth. This brings the company's total for the last twelve months to $16.90B, up 18.59% year-over-year. In the year 2025, Regeneron Pharmaceuticals had annual revenue of $14.34B with 0.99% growth. That makes Regeneron Pharmaceuticals the 903rd largest company in the world by revenue and 301st in the United States.
Revenue (ttm)
$16.90B
Revenue Growth
+18.59%
P/S Ratio
5.70
Revenue / Employee
$1,101,232
Employees
15,343
Market Cap
96.27B
Revenue by Segment
- Total Collaboration 7.33B 51.1%
- Net Product Sales 6.31B 44.0%
- Other Product 702.60M 4.9%
Fiscal year ended Dec 31, 2025 See the full Regeneron Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.34B | 140.90M | 0.99% |
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | 6.56B | 1.41B | 27.44% |
| Dec 31, 2018 | 5.15B | -726.60M | -12.37% |
| Dec 31, 2017 | 5.87B | 1.01B | 20.82% |
| Dec 31, 2016 | 4.86B | 756.67M | 18.44% |
| Dec 31, 2015 | 4.10B | 1.28B | 45.55% |
| Dec 31, 2014 | 2.82B | 714.81M | 33.96% |
| Dec 31, 2013 | 2.10B | 726.27M | 52.69% |
| Dec 31, 2012 | 1.38B | 932.65M | 209.20% |
| Dec 31, 2011 | 445.82M | -13.25M | -2.89% |
| Dec 31, 2010 | 459.07M | 79.81M | 21.04% |
| Dec 31, 2009 | 379.27M | 140.81M | 59.05% |
| Dec 31, 2008 | 238.46M | 113.43M | 90.73% |
| Dec 31, 2007 | 125.02M | 61.58M | 97.05% |
| Dec 31, 2006 | 63.45M | -2.75M | -4.15% |
| Dec 31, 2005 | 66.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vertex Pharmaceuticals | 12.95B |
| BeOne Medicines AG | 6.45B |
| Incyte | 6.01B |
| argenx SE | 5.92B |
| Genmab | 4.30B |
| BioNTech SE | 2.75B |
| Royalty Pharma | 2.62B |
| Moderna | 2.53B |
REGN News
- 1 day ago - Alnylam says Regeneron advances CIDEBsiRNA with FIH results in MASLD patients - TheFly
- 1 day ago - Regeneron Pharmaceuticals Transcript: Investor update - Transcripts
- 1 day ago - Regeneron Pharmaceuticals Slides: Investor update - Filings
- 3 days ago - Regeneron announces results from trial of CIDEBsiRNA - TheFly
- 3 days ago - CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD - GlobeNewsWire
- 9 days ago - Regeneron Announces Investor Conference Presentations - GlobeNewsWire
- 9 days ago - Regeneron price target raised to $913 from $810 at RBC Capital - TheFly
- 9 days ago - Regeneron price target raised to $997 from $835 at Leerink - TheFly